Stockscreener 앱 받기
46.69
1.41%
-0.67
시간 외 거래:
46.76
0.07
+0.15%
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Lobbying Update: $4,780,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed - Quiver Quantitative
Bristol-Myers Squibb Company (BMY): All Or Nothing With A Breakthrough Drug, Says Jim Cramer - Insider Monkey
FDA accepts Bristol Myers Squibb’s application for Sotyktu in psoriatic arthritis By Investing.com - Investing.com South Africa
FDA Review: Bristol Myers' Sotyktu Could Become First TYK2 Inhibitor for Psoriatic Arthritis - Stock Titan
Bristol Myers Squibb Stock (BMY) Opinions on Phase 3 Trial Results - Quiver Quantitative
What drives Bristol Myers Squibb Company stock priceRapid wealth multiplication - PrintWeekIndia
What analysts say about Bristol Myers Squibb Company Equity Right stockFree Stock Selection - Autocar Professional
Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025 - Insider Monkey
Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial - AOL.com
BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia - insights.citeline.com
Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb (BMY), Sets a $34 PT - Insider Monkey
Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial - Benzinga
Bristol Myers drug fails main goal in cancer-linked anemia trial - Reuters
Bristol-Myers Squibb stock holds steady as Reblozyl study misses endpoint - Investing.com
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia - BioSpace
Bristol Myers' drug fails main goal in cancer-related anemia trial - Reuters
Bristol Myers' drug fails main goal in late-stage trial for cancer-related anemia - Reuters
Bristol Myers late-stage trial for anemia drug fails (BMY) - Seeking Alpha
Bristol Myers Squibb’s Reblozyl misses primary endpoint in myelofibrosis trial By Investing.com - Investing.com South Africa
Bristol Myers Squibb’s Reblozyl misses primary endpoint in myelofibrosis trial - Investing.com
Boomers Get a Big Beautiful Tax Break: 4 Safe Stocks Yielding 5% to Buy Now - 24/7 Wall St.
BMS, Pfizer take DTC route for blood thinner Eliquis - pharmaphorum
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
13 Cheap Stocks Under $50 to Buy Now - Insider Monkey
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients - Reuters
Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off - Benzinga
Bristol Myers Squibb and Pfizer Launch Online Discount Program for Eliquis Blood Thinner - geneonline.com
Bristol-Myers Squibb: Morgan Stanley highlights catalyst driven idea By Investing.com - Investing.com South Africa
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients - Reuters
How Bristol Myers Squibb and Pfizer's Direct-to-Patient Eliquis Initiative is Reshaping Anticoagulant Access and Profitability - AInvest
Drugmakers to Sell Popular Blood Thinner Eliquis at 40% Discount - Bloomberg
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option - BioSpace
Bristol Myers, Pfizer Slash Eliquis Price by 40% with New Direct-to-Patient Program for Top Blood Thinner - Stock Titan
BROKERS’ NOTES: Buy Novo Nordisk, sell Bristol Myers Squibb - BusinessLIVE
Will Increased Expenses Affect Bristol Myers' Performance? - The Globe and Mail
Key facts about Nik Jhangiani, Diageo's new interim CEO - Reuters
Bristol-Myers Squibb’s KarXT Study: A Potential Game-Changer in Schizophrenia Treatment - TipRanks
Bristol-Myers Squibb’s New Alzheimer’s Study: A Potential Game Changer? - TipRanks
Is Bristol-Myers Squibb Still an Undervalued Biopharma Play? - AInvest
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play? - Benzinga
Bristol-Myers Squibb’s New Study: A Potential Game-Changer in Drug Development? - TipRanks
Winn CIPP Welcomes Cohort 4 Medical Students Focused on Connecting Communities to Clinical Research - ACCESS Newswire
What To Expect From Bristol-Myers Squibb's Q2 2025 Earnings Report - barchart.com
Can Bristol-Myers Squibb Company (BMY) Provide Stable Long-Term Income? - Insider Monkey
Bristol-Myers Squibb stock holds steady as UBS maintains Neutral rating By Investing.com - Investing.com South Africa
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Why Bristol-Myers Squibb (BMY) Shares Are Sliding Today - Yahoo Finance
Bristol-Myers Squibb’s Melanoma Study Completion: Market Insights - TipRanks
Bristol-Myers Squibb stock holds steady as UBS maintains Neutral rating - Investing.com India
Fierce Pharma Asia—Approvals for Innovent, Dizal; BMS partner's bispecific ADC readout - Fierce Pharma
BMO Capital Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY) - The Globe and Mail
Bristol Myers Squibb: Hidden Vulnerabilities in the Blockbuster Model - AInvest
Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company - Seeking Alpha
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
Worldwide locations - Bristol Myers Squibb
Bristol-Myers Squibb: Hold Rating Amid Revenue Growth and Strategic Challenges - TipRanks
Bristol-Myers Squibb Company (BMY) Announces New Clinical Trial for Breast Cancer Drug Iza-bren - Insider Monkey
Ninth Circuit Confirms Bristol-Myers’ Rule Applies to Notice in FLSA Collective Actions - JD Supra
Schizophrenia Market Research and Forecast Report 2025-2034 | Emerging Therapies and Genetic Research Drive Growth with Bristol Myers Squibb, AstraZeneca, and Eli Lilly Leading - Yahoo Finance
Bristol-Myers Squibb’s New Study on Sickle Cell Disease: A Potential Market Game-Changer - TipRanks
0.81%
0.06%
자본화:
|
볼륨(24시간):